
|Articles|May 1, 2004
PDT developer seeks FDA approval for its drug for wet form of AMD
Miravant Medical Technologies is asking the FDA to okay a new drug application for marketing approval of its SnET2-PDT as a treatment for patients with wet form of age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: The evolution of eye care on display at AAO 2025
2
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
3
Ocular pickleball injuries rise sharply with increasing game popularity
4
AAO 2025: Clinical outcomes of early vs delayed pegcetacoplan treatment in GA
5